Otter Products is currently recruiting for a Business Development Director – Bio Cold Chain Packaging to join our Liviri team. This role can be based remotely in the U.S. and requires travel (up to 50%) to client locations as needed.
As the Business Development Director – Bio Cold Chain Packaging, you will be responsible for all aspects of sales and business development activities for global cold chain consumer packaging goods used in medical devices, biotech, and pharmaceutical applications. Utilizing consultative “solutions selling” techniques, you will develop unique solutions to meet your customers’ specific product or container needs by representing the company at events and trade shows and traveling to customer sites as often as necessary. You will have the opportunity to drive innovation in the cold chain consumer packaging environment by communicating customers' needs to the organization and through good management, assist in turning those requirements into profits.
Liviri is a rapidly growing company based in Fort Collins, Co. We design and manufacture innovative, sustainable packaging components for cold-chain shipping of pharmaceutical and food products. The markets we serve have an urgent need for disruptive, sustainable alternatives to replace the wide array of non-sustainable packaging materials conventionally used in the cold chain, such as Styrofoam coolers.
Our aspiration is to provide packaging solutions that customers and end-consumers feel great about using. Deliver Different...Liviri.
o Temperature validation of containers on bio trucking partnerships
o Data logging, return logistics
o Shipping site and receiving site capabilities
o Technical packaging configuration including minimum and maximum loads of containers for varying payloads
o Thermal performance requirements for transportation duration
o Target customer packaging qualification process
o Product/payload stability and excursion tolerances and/or temperature shipping acceptable ranges
o Time to Transport, lanes tested, critical failure rates, and patient impact
o Lane risk assessment and lane disruption and acceptable tolerance ranges as well as probability of occurrence and probability of detection